Poseida Therapeutics, Inc.

Today, we released new #clinical data for our lead allogeneic CAR-T program at #IMS24. These #data continue to validate the potential positive efficacy and safety of our platforms and technologies for the treatment of #myeloma. Read the press release: https://lnkd.in/e88MrKJN We will hold a #webcast conference call tomorrow, Saturday September 28 at 10am PT | 1pm ET to discuss the results. Details here: https://lnkd.in/euY5mmFc #CapacitytoCure #celltherapy International Myeloma Society

Did you know that 1 in 8 women in the U.S. will face a breast cancer diagnosis in her lifetime? It’s crucial that we stand ready to support them. This #BreastCancerAwareness Month, we reaffirm our commitment to developing innovative therapies with the #capacitytocure. Let’s keep the patients and families we serve at the forefront of our mission. #celltherapy #geneticmedicines

We are excited to announce that team members from Poseida will be presenting a poster demonstrating the power of our non-viral #allogeneic technology to engineer CARs and TCRs simultaneously into T cells at #SITC24 in Houston. Presentation info. available now: https://lnkd.in/efM9i6Py #CapacitytoCure #celltherapy Society for Immunotherapy of Cancer (SITC)

Want firsthand insight into our clinical trial for P-BCMA-ALLO1? Read this article from AJMC - The American Journal of Managed Care for a Q&A with Bhagirathbhai Dholaria, M.D., on our investigational CAR-T therapy in #multiplemyeloma and potential benefits for patients: https://lnkd.in/eyeMdHcH ?#CapacitytoCure #celltherapy

We are excited to share that our CEO, Kristin Yarema, Ph.D., has been recognized on the PharmaVoice 100 list as a pioneer in cell and gene therapy. More on her #recognition, her #career to date, and the full list of inspiring industry leaders out now: https://lnkd.in/e8nV6kYA ? #CapacitytoCure #celltherapy #geneticmedicines #PharmaVoice100 #PV100

#Myeloma luminary Tom Martin, M.D., shares his thoughts and impressions on our recently announced Phase1b clinical #data for P-BCMA-ALLO1. Be sure to tune in for more on his reflections on the overall response rate in a refractory patient population. Full conference call webcast here: https://lnkd.in/eSD9W4kB #CapacitytoCure #celltherapy

Be sure to join our CEO, Kristin Yarema, Ph.D., and Astellas’ CSO, Yoshitsugu Shitaka, for an exciting fireside chat tomorrow on all things oncology, CAR-T, and our ongoing collaboration to develop novel allogeneic cell therapies leveraging Astellas’ convertibleCAR technology in unison with Poseida’s non-viral approach at #CGMesa24 in Phoenix. We look forward to seeing you there in person, if attending. https://lnkd.in/eiUpMy4 #CapacitytoCure #celltherapy #geneticmedicines Alliance for Regenerative Medicine Astellas Pharma

We are proud to share 100% of our ITT population received treatment without need for bridging therapy or apheresis in our Phase 1b study of P-BCMA-ALLO1. More on this achievement and other clinical data now in Genetic Engineering & Biotechnology News: ?https://lnkd.in/dRrkAy4p #CapacitytoCure #celltherapy

We are thrilled to announce that Poseida has been recognized as one of Newsweek's Top 200 Most Loved Workplaces in the U.S.! A huge thank you to our incredible team for making this possible. Your hard work and support inspire us every day. Here’s to continuing our journey together. Details here: https://lnkd.in/dbkdE3rB #Top200 #CapacitytoCure #PoseidaProud Most Loved Workplaces?

Promising early results from Poseida Therapeutics, and good diversity in this phase 1 study, too.